Dr. Nizar Souayah, MD

Dr. Souayah practices at New Jersey Pediatric Neuroscience Institute in Morristown, New Jersey.

Dr. Souayah's NPI, 1558402032, was assigned on February 9, 2007. Dr. Souayah graduated from National School of Science- Tunisia Faculty of Medicine in 1990. Dr. Souayah holds New Jersey license 25MA07746800.

Dr. Souayah's primary practice is New Jersey Pediatric Neuroscience Institute, at 131 Madison Ave, Morristown, NJ 07960 in Morris County. The practice phone is (973) 326-9000.

Dr. Souayah's primary practice is New Jersey Pediatric Neuroscience Institute in Morristown, New Jersey. The medical group on file is New Jersey Pediatric Neuroscience Institute. Dmand AI also links Dr. Souayah to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Souayah practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Souayah's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Souayah is licensed in New Jersey.

CMS data shows 14 Medicare services from Dr. Souayah across 1 procedure code in 2024, for 39 Medicare patients. Medicare paid $927 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 39 Medicare patients who saw Dr. Souayah in 2024. The largest group is 65 to 74, with 13 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 38% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Souayah's median patient age at 58, with 51% women.

In 2024, Dr. Souayah wrote 317 Medicare Part D claims for 30 patients. 32% of them were for generic drugs. CMS names the drug for 269 of them, across 10 drugs with 11 or more claims each, at $1,899,682 in total drug cost. In 2023, CMS named 415 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Souayah for performance year 2024, reported as part of a group. Dr. Souayah accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 71 papers to Dr. Souayah, published from 2005 to 2025. 2023 was the busiest year, with 8. The most frequent topics are Immunoglobulins, Intravenous, Amyotrophic Lateral Sclerosis and Cytokines. Dr. Souayah has published most often in J Clin Neuromuscul Dis. Dr. Souayah's most frequent co-authors are Hussam A. Yacoub, DO, Daniel L. Menkes, MD and Howard W. Sander, MD.

Dmand AI links Dr. Souayah to 3 clinical trials, 2 of them phase 2 studies. Conditions studied include Myasthenia Gravis, Neuromuscular Junction Diseases and Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Grifols Therapeutics LLC sponsors the most, 2.

CMS Open Payments shows 159 general payments to Dr. Souayah from 14 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 55% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $61,960. It also lists 1 research payment totaling $4,950 in 2016.

Dr. Souayah graduated from National School of Science- Tunisia Faculty of Medicine in 1990.